Parkinson's Disease Quality of Life (PDQUALIF) - less sexually desirable scale

General Details:

Name:
Parkinson's Disease Quality of Life (PDQUALIF) - less sexually desirable scale
Steward:
NINDS
Definition:
Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Registration Status:
Qualified

Permissible Values:

Data Type:
Value List
Unit of Measure:
Ids:
Value Code Name Code Code System Code Description
Strongly Agree Strongly Agree Strongly Agree
Somewhat Agree Somewhat Agree Somewhat Agree
Agree Agree Agree
Somewhat disagree Somewhat disagree Somewhat disagree
Strongly Disagree Strongly Disagree Strongly Disagree

Designations:

Designation:
Parkinson's Disease Quality of Life (PDQUALIF) - less sexually desirable scale
Tags:

Designations:

Definition:
Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Tags:

Reference Documents:

ID:
Title:
URI:
Provider Org:
Language Code:
Document:
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.

Identifiers:

Source:
NLM
Id:
DJG2SPZKYtO
Version:
3.1
Source:
NINDS
Id:
C17384
Version:
3
Source:
BRICS Variable Name
Id:
PDQUALIFLesSexDesirblScale
Version: